2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1741

Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 652

Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study
Abstract Number: 543

Disease Severity Among Bio-Naive RA Patients on Csdmards
Abstract Number: 1742

Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Abstract Number: 2646

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
Abstract Number: 265

Disparities in Utilization and Direct Costs of Hospitalizations and Emergency Room Visits in SLE: The Georgia Lupus Registry
Abstract Number: 221

Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan
Abstract Number: 1046

Distinct Balance of TNF-α/IL-10 in Circulating and Infiltrating CD163+ Macrophages between Rapidly and Slowly Progressive Symptomatic Knee Osteoarthritis
Abstract Number: 1014

Distinct Macrophage Phenotype and Bioenergetic Profiles in Rheumatoid Arthritis
Abstract Number: 1074

Distinct Metabolic Profile in the Urine of Rheumatoid Arthritis Patients:a Possible Link to Arthritis Phenotypes
Abstract Number: 1113

Distinct Pathways in Anti-RNP-Associated Pulmonary Hypertension and Anti-RNP-Associated Raynaud’s Phenomenon
Abstract Number: 138

Distinct Roles of Tfh2, SLAMF7+ Tfh1 Cells and Th1 Cells in the Pathogenesis of IgG4-RD
Abstract Number: 207

Divergent Patterns of Cardiovascular Risk in Biomarkers of Lipids and Subclinical Myocardial Injury during Increased Inflammation in Rheumatoid Arthritis
Abstract Number: 1520

DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
Abstract Number: 622

DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].